Skip to main content Skip to search Skip to main navigation

EMA: New Q&As for Wholesale Distributors/Brokers on Suspicious Offers

The EMA has published two new GDP Q&As for wholesale distributors and brokers on suspicious offers.

How will distributors and brokers know if they are given suspicious offers?
Wholesalers must be aware of the risk of receiving falsified or substandard medicinal products. Guidance from EU GDP Guidelines suggests conducting "due diligence" checks when contracting new suppliers, considering factors such as the supplier’s reputation, offers of medicinal products likely to be falsified, large or unusual offers, and abnormal pricing (see article 5.2 EU GDP Guidelines).
Suspicious offers may include:

  • Products in high demand or supply shortages
  • Communication through unconventional channels (e.g., WhatsApp)
  • Urgency or unusually low prices
  • Products with decommissioned identifiers or broken tamper-evident features
  • Suppliers not listed in official databases (EudraGMDP for wholesalers, national repositories for brokers)
  • Unverified availability or unexpected economic/geographical offers

Wholesalers must only obtain products from authorised entities, as specified in EU regulations. Products imported from third countries require a manufacturing/import authorisation.

What should wholesale distributors and brokers do if they learn of suspicious offers?
Wholesalers or brokers who encounter a suspicious offer must immediately contact the national competent authority and the marketing authorisation holder. This applies whether they are directly offered suspected falsified products or become aware of such offers to others, including when verifying unique identifiers for others.


Source:

EMA: Guidance on good manufacturing practice and good distribution practice: Questions and answers

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

What is a gas?

What is a gas?

You can view the answer here:
Read more
EDQM: New Ph. Eur. Chapter on Data Quality with a Focus on Digital Data

EDQM: New Ph. Eur. Chapter on Data Quality with a Focus on Digital Data

The European Pharmacopoeia (Ph. Eur.) has introduced a new general chapter that provides a framework for managing the quality of data, including digital data, throughout its life cycle.

Read more
EMA: Pilot Programme for Breakthrough Devices

EMA: Pilot Programme for Breakthrough Devices

The EMA plans to launch a pilot programme in Q2 2026 to implement the guidance for breakthrough devices issued in December 2025.

Read more
PIC/S: Jordan FDA Joins PIC/S

PIC/S: Jordan FDA Joins PIC/S

On 1 January 2026, the Jordan Food & Drug Administration (JFDA) became the 57th PIC/S Participating Authority.

Read more
Swissmedic: Scientific GMDP Meetings

Swissmedic: Scientific GMDP Meetings

Swissmedic offers companies holding or seeking a Swissmedic manufacturing or distribution license the opportunity to discuss project-specific GMP and GDP topics in Scientific GMDP Meetings.

Read more
Purified Water – The new Chinese Pharmacopoeias and What Happens Next?

Purified Water – The new Chinese Pharmacopoeias and What Happens Next?

A new Chinese Pharmacopoeia was published in 2025. This has some significant implications for the pharmaceutical water industry, which we will discuss in more detail in this article. Firstly, it is important to note that cold WFI systems are now permitted worldwide and can be used across the board.
Read more
Previous
Next